You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Mass. Movers

Alnylam cites charge for earnings loss

Alnylam cited a one-time charge for its net loss.

istockphoto.com

Alnylam cited a one-time charge for its net loss.

Continue reading below

Alnylam Pharmaceuticals Inc. reported a fourth-quarter net loss of $63.2 million, or $1.20 per share, compared with a loss of $14.3 million, or 33 cents, in the same period last year. For the year, the net loss was $106 million, or $2.11 per share, compared with a loss of $57.6 million, or $1.36, for the prior year. The Cambridge biotech cited a one-time charge of $65 million related to the restructuring of its licensing agreement with Tekmira Pharmaceuticals Corp. for the loss.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week